Q/C Technologies, Inc. SEC filings QCLS
Q/C Technologies, Inc. has 604 filings in SEC EDGAR's recent list, going back to Mar 23, 2005. Its latest annual report, Form 10-K, was filed on Apr 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 18, 2026 (material agreement, officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| NT 10-K | Filing | Mar 31, 2026 | Dec 31, 2025 |
| EFFECT | Filing | Feb 17, 2026 | — |
| CORRESP | Letter to the SEC | Feb 12, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 28, 2026 | — |
| DRS | Filing | Jan 23, 2026 | — |
| EFFECT | Filing | Nov 28, 2025 | — |
| CORRESP | Letter to the SEC | Nov 25, 2025 | — |
| NT 10-Q | Filing | Nov 14, 2025 | Sep 30, 2025 |
| UPLOAD | Letter from the SEC | Sep 18, 2025 | — |
| D | Filing | Sep 5, 2025 | — |
| CORRESP | Letter to the SEC | Aug 19, 2025 | — |
| NT 10-Q | Filing | Aug 14, 2025 | Jun 30, 2025 |
| UPLOAD | Letter from the SEC | Aug 5, 2025 | — |
| DEFR14A | Filing | May 19, 2025 | — |
| PRER14A | Filing | May 9, 2025 | — |
| NT 10-K | Filing | Mar 31, 2025 | Dec 31, 2024 |
| UPLOAD | Letter from the SEC | Oct 7, 2024 | — |
| CORRESP | Letter to the SEC | Sep 30, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 23, 2024 | — |
| NT 10-Q | Filing | Aug 14, 2024 | Jun 30, 2024 |
| EFFECT | Filing | Aug 12, 2024 | — |
| CORRESP | Letter to the SEC | Aug 9, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 27, 2024 | — |
| D | Filing | May 31, 2024 | — |
| D | Filing | May 31, 2024 | — |
| D | Filing | Aug 30, 2022 | — |
| NT 10-Q | Filing | May 18, 2021 | Mar 31, 2021 |
| EFFECT | Filing | May 11, 2021 | — |
| CORRESP | Letter to the SEC | May 10, 2021 | — |
| CORRESP | Letter to the SEC | Apr 28, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 16, 2021 | — |
| 425 | Filing | Apr 13, 2021 | — |
| 425 | Filing | Apr 12, 2021 | — |
| EFFECT | Filing | Mar 23, 2021 | — |
| 425 | Filing | Mar 22, 2021 | — |
| CORRESP | Letter to the SEC | Mar 19, 2021 | — |
| 425 | Filing | Feb 18, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 22, 2021 | — |
| 425 | Filing | Dec 2, 2020 | — |
| D | Filing | Nov 24, 2020 | — |
| 425 | Filing | Nov 19, 2020 | — |
| 425 | Filing | Nov 18, 2020 | — |
| 425 | Filing | Nov 18, 2020 | — |
| 8-A12B | Filing | Sep 9, 2020 | — |
| EFFECT | Filing | Aug 25, 2020 | — |
| CORRESP | Letter to the SEC | Aug 24, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 21, 2020 | — |
| D | Filing | Aug 11, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 10, 2020 | — |
| PRER14A | Filing | Jul 23, 2020 | — |
| CORRESP | Letter to the SEC | Jul 23, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 22, 2020 | — |
| CORRESP | Letter to the SEC | Jul 21, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 20, 2020 | — |
| EFFECT | Filing | Jun 12, 2020 | — |
| CORRESP | Letter to the SEC | Jun 10, 2020 | — |
| CORRESP | Letter to the SEC | Jun 5, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 2, 2020 | — |
| D | Filing | May 21, 2020 | — |
| D | Filing | Apr 14, 2020 | — |
| EFFECT | Filing | Apr 7, 2020 | — |
| D | Filing | Apr 7, 2020 | — |
| CORRESP | Letter to the SEC | Apr 6, 2020 | — |
| CORRESP | Letter to the SEC | Mar 24, 2020 | — |
| CORRESP | Letter to the SEC | Mar 23, 2020 | — |
| EFFECT | Filing | Dec 5, 2019 | — |
| UPLOAD | Letter from the SEC | Dec 5, 2019 | — |
| PRER14A | Filing | Dec 4, 2019 | — |
| CORRESP | Letter to the SEC | Dec 3, 2019 | — |
| CORRESP | Letter to the SEC | Dec 3, 2019 | — |
| UPLOAD | Letter from the SEC | Nov 8, 2019 | — |
| UPLOAD | Letter from the SEC | Nov 8, 2019 | — |
| NT 10-Q | Filing | May 15, 2019 | Mar 31, 2019 |
| NT 10-Q | Filing | May 16, 2018 | Mar 31, 2018 |
| NT 10-K | Filing | Apr 3, 2018 | Dec 31, 2017 |
| UPLOAD | Letter from the SEC | Dec 27, 2017 | — |
| EFFECT | Filing | Dec 18, 2017 | — |
| CORRESP | Letter to the SEC | Dec 15, 2017 | — |
| CORRESP | Letter to the SEC | Dec 15, 2017 | — |
| CORRESP | Letter to the SEC | Dec 15, 2017 | — |
| UPLOAD | Letter from the SEC | Dec 15, 2017 | — |
| CORRESP | Letter to the SEC | Dec 14, 2017 | — |
| CORRESP | Letter to the SEC | Dec 14, 2017 | — |
| CORRESP | Letter to the SEC | Dec 14, 2017 | — |
| CORRESP | Letter to the SEC | Dec 13, 2017 | — |
| CORRESP | Letter to the SEC | Dec 13, 2017 | — |
| CORRESP | Letter to the SEC | Dec 13, 2017 | — |
| UPLOAD | Letter from the SEC | Dec 12, 2017 | — |
| UPLOAD | Letter from the SEC | Dec 4, 2017 | — |
| EFFECT | Filing | Jun 30, 2017 | — |
| CORRESP | Letter to the SEC | Jun 29, 2017 | — |
| CORRESP | Letter to the SEC | Jun 5, 2017 | — |
| UPLOAD | Letter from the SEC | May 4, 2017 | — |
| D | Filing | Apr 13, 2017 | — |
| NT 10-K | Filing | Mar 31, 2017 | Dec 31, 2016 |
| EFFECT | Filing | Nov 16, 2016 | — |
| CORRESP | Letter to the SEC | Nov 15, 2016 | — |
| UPLOAD | Letter from the SEC | Nov 8, 2016 | — |
| NT 10-Q | Filing | Aug 14, 2015 | Jun 30, 2015 |
| EFFECT | Filing | Jan 23, 2014 | — |
| CERTNAS | Auto-generated paper document | Jan 22, 2014 | — |
| CORRESP | Letter to the SEC | Jan 17, 2014 | — |
| 8-A12B | Filing | Jan 17, 2014 | — |
| CORRESP | Letter to the SEC | Jan 17, 2014 | — |
| UPLOAD | Letter from the SEC | Nov 26, 2013 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2013 | — |
| UPLOAD | Letter from the SEC | Oct 25, 2013 | — |
| UPLOAD | Letter from the SEC | Sep 4, 2013 | — |
| REGDEX | Auto-generated paper document | Feb 2, 2007 | — |
| REGDEX | Auto-generated paper document | Mar 23, 2005 | — |
Showing 110 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- QCLS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1321834
- Former names
- Q/C TECHNOLOGIES, INC. (until Oct 2, 2026); TNF Pharmaceuticals, Inc. (until Sep 10, 2025); MyMD Pharmaceuticals, Inc. (until Jul 1, 2024); Akers Biosciences, Inc. (until Apr 16, 2021); Akers Biosciences Inc (until Apr 11, 2017)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.